Table 3.

Monitoring patients on imatinib

	Hematologic response	Cytogenetic response	Molecular response
Recommended monitoring interval	Every 2 weeks until complete response, then every 3 months unless otherwise required	Every 6 months until complete response achieved and confirmed, hence at least every 12 months	Every 3 months; mutational analysis in case of failure, suboptimal response, or transcript level increase